News & Updates

Daunorubicin for newly diagnosed AML: Does more equate to better outcomes?

In acute myeloid leukaemia (AML) patients who received the 7+3* induction, a higher daunorubicin dose or a double induction did not seem to yield better outcomes, findings from the two-part phase III SAL Dauno-Double trial suggest.

RAS inhibitor discontinuation of no help in slowing kidney decline

Stopping treatment with renin–angiotensin system (RAS) inhibitors in patients with advanced chronic kidney disease does not appear to raise the levels of estimated glomerular filtration rate (eGFR) or decelerate its decline, according to a study.

TACE + apatinib: A potential new strategy for intermediate/advanced HCC?

CADENZA updates enhance sutimlimab benefit for rare chronic anaemia

Individuals with cold agglutinin disease (CAD), a rare, chronic, autoimmune haemolytic anaemia, had sustained improvements in patient-reported outcomes (PROs) and quality of life (QoL) following treatment with the C1s complement inhibitor sutimlimab, findings from part B of the phase III CADENZA trial have shown.

Metformin exposure in pregnancy poses no risk of SGA, LGA in infants

Exposure to metformin in utero does not appear to put infants at risk of being small for gestational age (SGA) or being large for gestational age (LGA) as compared with nonexposure, a study has found.